Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2009

View Archived Issues

Amgen scientists describe new Smo receptor antagonists in recent patent

New BACE inhibitors reported in recent Boehringer Ingelheim patent

Gilead reports data on boosting activity of fixed-dose combination therapy with GS-9350

New histamine H3 receptor ligands reported in recent High Point patent

Dainippon Sumitomo Pharma scientists claim new renin inhibitors

Bristol-Myers Squibb reports new SERT inhibitors and/or NK1 receptor antagonists

Shionogi updates Q3 progress

New HCV NS3/NS4A inhibitors discovered at Gilead

BMS researchers design novel chemokine CCR1 antagonists

Roche presents bifunctional HIV entry inhibitor CD4-BFFI

PROVE2: Telaprevir improves efficacy of hepatitis C treatment

Biodistribution, toxicity of suicide gene adenovirus therapy studied in vivo

PRO-140 shows potent and prolonged antiviral activity in HIV-1 infected individuals

Novel HIV-1 antiretroviral agents inhibit RNase H activity of viral reverse transcriptase

BioAlliance seeks E.U. MAA for fast-dissolving ondansetron

arGentis receives E.U. orphan drug designation for ARG-201

Agenix progresses ThromboView to final development stage

Diamyd receives approval for follow-up study for its diabetes vaccine

GlaxoSmithKline and Mitsubishi Tanabe to co-promote Adoair in Japan

Vical receives milestone payment from AnGes for Allovectin-7 phase III trial

Shionogi presents positive top-line efficacy results from velneperit studies

NeuroSearch enters ion channel target development alliance with Lilly

Northwest reports data from phase I and phase I/II clinical trials of DCVax-Brain

Proteo reports results from clinical study of Elafin in ARDS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...